...
首页> 外文期刊>Annals of allergy, asthma, and immunology >Efficacy and safety of oral desensitization in children with cow's milk allergy according to their serum specific IgE level
【24h】

Efficacy and safety of oral desensitization in children with cow's milk allergy according to their serum specific IgE level

机译:根据血清特异性IgE水平对牛奶过敏儿童进行口服脱敏的功效和安全性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background: Oral desensitization in children allergic to cow's milk proteins is not risk free. The analysis of factors that may influence the outcome is of utmost importance. Objective: To analyze the efficacy and safety of the oral desensitization according to specific IgE (sIgE) level and adverse events during the maintenance phase. Methods: Thirty-six patients allergic to cow's milk (mean age, 7 years) were included in an oral desensitization protocol. Patients were grouped according to sIgE levels (ImmunoCAP) into groups 1 (sIgE <3.5 kU/L), 2 (3.5-17 kU/L), and 3 (>17-50 kU/L). Nineteen children were included as a control group. Serum sIgE levels to cow's milk and its proteins were determined at inclusion and 6 and 12 months after finishing the desensitization protocol. Results: Thirty-three of 36 patients were successfully desensitized (200 mL): 100% of group 1 and 88% of groups 2 and 3. Desensitization was achieved in a median of 3 months (range, 1-12 months); 90% of the patients in group 1, 50% of the patients in group 2, and 30% of the patients in group 3 achieved tolerance in less than 3 months (P =.04). In the control group only 1 child tolerated milk in oral food challenge after 1 year. During the induction phase, there were 53 adverse events in 27 patients (75%). Patients of groups 2 and 3 had more severe adverse events compared with group 1. During the maintenance phase, 20 of 33 patients (60%) had an adverse event. Conclusion: Oral desensitization is efficacious. Tolerance is achieved earlier when sIgE is lower. Severe adverse events are frequent, especially in patients with higher sIgE levels. Trial Registration: clinicaltrials.gov Identifier: NCT01641731.
机译:背景:对牛奶蛋白过敏的儿童口服脱敏并非没有风险。对可能影响结果的因素进行分析至关重要。目的:根据特定的IgE(sIgE)水平和维持阶段的不良事件,分析口服脱敏的疗效和安全性。方法:将36例对牛奶过敏的患者(平均年龄7岁)纳入口服脱敏方案。根据sIgE水平(ImmunoCAP)将患者分为1组(sIgE <3.5 kU / L),2组(3.5-17 kU / L)和3组(> 17-50 kU / L)。十九名儿童被纳入对照组。在脱敏方案完成后6个月和12个月时,测定了牛奶和其蛋白质的血清sIgE水平。结果:36例患者中有33例成功脱敏(200 mL):第1组为100%,第2组和第3组为88%。脱敏的中位数为3个月(1-12个月)。第1组中有90%的患者在第3个月内达到了耐受性,第2组中有50%的患者,第3组中有30%的患者达到了耐受性(P = .04)。在对照组中,只有1名儿童在1年后接受口服食品挑战时耐受牛奶。在诱导阶段,27例患者中有53例不良事件(75%)。与第1组相比,第2组和第3组的患者发生更严重的不良事件。在维持阶段,33位患者中有20位(60%)发生了不良事件。结论:口服脱敏是有效的。当sIgE较低时,可以较早地达到公差。严重不良事件频繁发生,特别是在sIgE水平较高的患者中。试用注册:clinicaltrials.gov标识符:NCT01641731。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号